Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, Cross-Over, Bioequivalence Study Comparing Phase 2b, Phase 3 And Commercial Image Tablet Formulations Of Tasocitinib (CP-690,550) Under Fasted Conditions
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2010
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- 13 Oct 2010 Actual end date added to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 13 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.